Insulet (NASDAQ:PODD) Shares Gap Up Following Strong Earnings

Insulet Corporation (NASDAQ:PODD)’s share price gapped up before the market opened on Wednesday after the company announced better than expected quarterly earnings. The stock had previously closed at $246.34, but opened at $266.00. Insulet shares last traded at $260.6720, with a volume of 732,680 shares.

The medical instruments supplier reported $1.55 EPS for the quarter, topping the consensus estimate of $1.48 by $0.07. Insulet had a return on equity of 24.36% and a net margin of 9.76%.During the same quarter last year, the firm posted $1.15 EPS. The business’s revenue was up 31.2% compared to the same quarter last year.

Key Headlines Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Q4 results beat expectations — Insulet reported $1.55 EPS vs. a $1.48 consensus and revenue grew ~31% year-over-year, signaling robust underlying demand for Omnipod. Insulet beats quarterly estimates on strong demand for wearable insulin pumps
• Positive Sentiment: FY revenue guidance raised (to about $3.3B) — management set full-year revenue expectations above Street revenue consensus, which supports a positive medium-term growth outlook. Insulet Press Release / Slide Deck
• Neutral Sentiment: Strategic expansion and supply-agreement update announced — operational moves that could support growth, but impact depends on execution and timing. Insulet Announces Strategic Expansion and Supply Agreement Update
• Neutral Sentiment: Analysts remain generally bullish with above-average target-price interest despite recent underperformance; consensus analyst sentiment is a moderate-buy. What Are Wall Street Analysts’ Target Price for Insulet Stock?
• Negative Sentiment: Near-term revenue guide for Q1 came in below Street expectations (guidance range ~ $705.6M–$716.9M vs. a ~$768M consensus), which creates near-term execution risk and likely pressure on short-term sentiment. Insulet Press Release / Slide Deck

Wall Street Analyst Weigh In

A number of research firms recently commented on PODD. Raymond James Financial upped their price objective on Insulet from $366.00 to $385.00 and gave the company an “outperform” rating in a report on Friday, November 21st. Wolfe Research lifted their target price on Insulet from $350.00 to $375.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Canaccord Genuity Group upped their price target on Insulet from $432.00 to $450.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. BTIG Research raised their price objective on Insulet from $370.00 to $380.00 and gave the stock a “buy” rating in a research report on Friday, November 21st. Finally, The Goldman Sachs Group restated a “buy” rating and issued a $365.00 price objective on shares of Insulet in a report on Friday, January 9th. Twenty equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, Insulet has an average rating of “Moderate Buy” and a consensus price target of $374.10.

Hedge Funds Weigh In On Insulet

Several hedge funds have recently bought and sold shares of the company. Larson Financial Group LLC grew its position in Insulet by 114.6% in the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 47 shares in the last quarter. University of Texas Texas AM Investment Management Co. purchased a new position in shares of Insulet in the fourth quarter valued at approximately $26,000. Elyxium Wealth LLC acquired a new position in shares of Insulet in the fourth quarter valued at approximately $28,000. DV Equities LLC purchased a new stake in Insulet during the 4th quarter worth approximately $28,000. Finally, True Wealth Design LLC increased its stake in Insulet by 288.0% during the 3rd quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 72 shares during the period.

Insulet Stock Performance

The company has a current ratio of 2.87, a quick ratio of 2.18 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $18.33 billion, a price-to-earnings ratio of 75.57, a price-to-earnings-growth ratio of 1.37 and a beta of 1.41. The stock’s fifty day simple moving average is $275.16 and its 200-day simple moving average is $305.84.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.